Initial fixed low-versus moderate-dose hydroxyurea assignment in the long-term follow-up of the SPRINT cohort.

In the pragmatic long-term follow-up of the SPRINT randomized trial cohort, initial fixed low- versus moderate-dose hydroxyurea showed no significant difference in recurrent stroke or all-cause mortality over 4.9 years.

• Why it matters: The study addresses whether an early hydroxyurea dose assignment changes long-term vascular and survival outcomes in the SPRINT trial population.
• What they did: In a long-term follow-up of the SPRINT randomized trial cohort, investigators compared outcomes by initial fixed low versus moderate hydroxyurea dose over 4.9 years.
• The result: Recurrent stroke and all-cause mortality rates were not significantly different, and events clustered in the first year, informing expectations for early risk.